Document Detail

Tardive dyskinesia and atypical antipsychotic drugs.
MedLine Citation:
PMID:  10190226     Owner:  NLM     Status:  MEDLINE    
Typical antipsychotic agents produce central nervous system effects, especially extrapyramidal symptoms (EPS) and tardive dyskinesia (TD). Nearly every patient who receives neuroleptic therapy has one or more identifiable risk factors for TD, among the most significant of which are older age, female gender, presence of EPS, diabetes mellitus, affective disorders, and certain parameters of neuroleptic exposure (i.e. dose and duration of therapy). The typical course of TD is a gradual onset after several years of drug therapy, followed by slow improvement or remission, but a large number of patients have persistent TD with irreversible symptoms. In the management of TD, the patient's mental status is of primary concern. Currently, no uniformly safe and effective therapies for TD exist, though a variety of therapeutic agents, including some of the atypical neuroleptics, have been reported to treat TD successfully in some patients. Because TD liability is so much lower with novel antipsychotic therapy, all patients who have TD or are at risk for TD, as well as EPS, should be considered candidates for switching to these new drugs.
D E Casey
Related Documents :
7852656 - Immune parameters in euthymic bipolar patients and normal volunteers.
11730076 - Neuropsychological impairment in patients treated with depot neuroleptics: a longitudin...
8348196 - Clinical correlates of valproate augmentation in refractory bipolar disorder.
937566 - Agitated psychotic depression associated with severe hypomanic episodes: a rare syndrome.
24630146 - Observational study of intra-abdominal pressure monitoring in acute pancreatitis.
19654126 - Atrial fibrillation ablation procedure using electroanatomic reconstruction of the righ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Schizophrenia research     Volume:  35 Suppl     ISSN:  0920-9964     ISO Abbreviation:  Schizophr. Res.     Publication Date:  1999 Mar 
Date Detail:
Created Date:  1999-07-21     Completed Date:  1999-07-21     Revised Date:  2010-09-02    
Medline Journal Info:
Nlm Unique ID:  8804207     Medline TA:  Schizophr Res     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  S61-6     Citation Subset:  IM    
Mental Health Division, Veterans Affairs Medical Center, Portland, OR 97207, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Factors
Antipsychotic Agents / adverse effects*
Basal Ganglia Diseases / chemically induced
Clozapine / adverse effects
Dyskinesia, Drug-Induced / diagnosis*
Middle Aged
Pirenzepine / adverse effects,  analogs & derivatives
Risperidone / adverse effects
Schizophrenia / drug therapy
Sex Factors
Grant Support
Reg. No./Substance:
0/Antipsychotic Agents; 106266-06-2/Risperidone; 12794-10-4/Benzodiazepines; 132539-06-1/olanzapine; 28797-61-7/Pirenzepine; 5786-21-0/Clozapine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cognitive improvement in schizophrenia with novel antipsychotic medications.
Next Document:  Prolactin and antipsychotic medications: mechanism of action.